SAS and Carolina partner to accelerate antiviral drug development
Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI).
(UNC.edu)
Related: Campus Connections
Farewell to the Well: UNC adopts interlocking NC as University-wide logoUNC is replacing its Old Well logo with the interlocking NC symbol, which was previously utilized for athletics only, as its primary branding. The new...
Sat Jan 17, 2026Eve Carson Scholarship Awards Students on Her 40th Birthday
The Eve Carson Scholarship, named for the student body president who was murdered in 2008, announced its latest cohort of recipients on what would have...
Fri Jan 16, 2026
Chase Rice Announces Hiatus From Touring, Admitting: ‘I’m Exhausted’
Chase Rice is stepping away from touring. In a poignant, vulnerable social media post, the country artist confessed that he was “exhausted. I haven’t been...
Tue Jan 13, 2026
UNC professor named National Book Award finalist
Almost every Thursday, Gabrielle Calvocoressi spends a couple of hours with students at the basketball courts near the Cobb Parking Deck. This weekly get-together, called...
Mon Jan 12, 2026
